NeuroVive Pharmaceutical AB (publ) engages in the research and development of mitochondrial medicine in Sweden and internationally.
+ 3 more risks
Excellent balance sheet and overvalued.
Share Price & News
How has NeuroVive Pharmaceutical's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: NVP's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: NVP underperformed the Swedish Biotechs industry which returned -29% over the past year.
Return vs Market: NVP underperformed the Swedish Market which returned -8.2% over the past year.
Price Volatility Vs. Market
How volatile is NeuroVive Pharmaceutical's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 months ago | Simply Wall StIs NeuroVive Pharmaceutical AB's (STO:NVP) CEO Pay Fair?
3 months ago | Simply Wall StDoes Market Volatility Impact NeuroVive Pharmaceutical AB's (STO:NVP) Share Price?
4 months ago | Simply Wall StDid Changing Sentiment Drive NeuroVive Pharmaceutical's (STO:NVP) Share Price Down A Disastrous 98%?
Is NeuroVive Pharmaceutical undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate NVP's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate NVP's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: NVP is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: NVP is unprofitable, so we can't compare its PE Ratio to the Swedish market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate NVP's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: NVP is good value based on its PB Ratio (1x) compared to the SE Biotechs industry average (3.2x).
How is NeuroVive Pharmaceutical forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NVP is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: NVP is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: NVP is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: NVP's revenue is expected to decline over the next 3 years (-25.2% per year).
High Growth Revenue: NVP's revenue is forecast to decline over the next 3 years (-25.2% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: NVP is forecast to be unprofitable in 3 years.
How has NeuroVive Pharmaceutical performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: NVP is currently unprofitable.
Growing Profit Margin: NVP is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: NVP is unprofitable, and losses have increased over the past 5 years at a rate of -0.8% per year.
Accelerating Growth: Unable to compare NVP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NVP is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (12.6%).
Return on Equity
High ROE: NVP has a negative Return on Equity (-60.25%), as it is currently unprofitable.
How is NeuroVive Pharmaceutical's financial position?
Financial Position Analysis
Short Term Liabilities: NVP's short term assets (SEK59.9M) exceed its short term liabilities (SEK20.3M).
Long Term Liabilities: NVP's short term assets (SEK59.9M) exceed its long term liabilities (SEK361.0K).
Debt to Equity History and Analysis
Debt Level: NVP is debt free.
Reducing Debt: NVP has not had any debt for past 5 years.
Inventory Level: NVP has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if NVP's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: NVP has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: NVP has sufficient cash runway for 1 years if free cash flow continues to reduce at historical rates of -2.6% each year.
What is NeuroVive Pharmaceutical's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate NVP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate NVP's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if NVP's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if NVP's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of NVP's dividend in 3 years as they are not forecast to pay a notable one for the Swedish market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Erik Kinnmann (61yo)
Mr. Erik Kinnmann, M.D., Ph.D., M.B.A., Assoc. Prof. has been the Chief Executive Officer of NeuroVive Pharmaceutical AB since March 14, 2016. Mr. Kinnmann served as the Chief Medical Officer of Infant Bac ...
CEO Compensation Analysis
Compensation vs Market: Erik's total compensation ($USD389.61K) is above average for companies of similar size in the Swedish market ($USD213.67K).
Compensation vs Earnings: Erik's compensation has increased whilst the company is unprofitable.
|Chief Executive Officer||4.08yrs||kr3.91m||0.22% SEK284.2k|
|CFO & VP of Investor Relations||6.33yrs||no data||0.032% SEK42.6k|
|Chief Scientific Officer & VP of Discovery||20.25yrs||kr247.00k||0.31% SEK410.0k|
|Director of Communications||2.5yrs||no data||no data|
|Chief Medical Officer and VP of Preclinical & Clinical Development||4.25yrs||no data||0.22% SEK294.2k|
|Consultant||no data||no data||no data|
Experienced Management: NVP's management team is considered experienced (4.2 years average tenure).
|Chairman of the Board||2.42yrs||kr430.00k||0.016% SEK21.7k|
|Director||1yr||no data||no data|
Experienced Board: NVP's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 118%.
NeuroVive Pharmaceutical AB's company bio, employee growth, exchange listings and data sources
- Name: NeuroVive Pharmaceutical AB
- Ticker: NVP
- Exchange: OM
- Founded: 2000
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: kr132.026m
- Shares outstanding: 185.95m
- Website: https://www.neurovive.com
Number of Employees
- NeuroVive Pharmaceutical AB
- Medicon Village
- Scheelevägen 2
- Skåne County
- 223 81
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|NVP||OM (OMX Nordic Exchange Stockholm)||Yes||Share Capital||SE||SEK||Oct 2008|
|0QDU||LSE (London Stock Exchange)||Yes||Share Capital||GB||SEK||Oct 2008|
|NTP||DB (Deutsche Boerse AG)||Yes||Share Capital||DE||EUR||Oct 2008|
|NEVP.F||OTCPK (Pink Sheets LLC)||Yes||Share Capital||US||USD||Oct 2008|
|NVPS||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Share Capital||GB||SEK||Oct 2008|
NeuroVive Pharmaceutical AB (publ) engages in the research and development of mitochondrial medicine in Sweden and internationally. Its product portfolio includes NeuroSTAT, a drug candidate that is in phase II clinical trial for the treatment of traumatic brain injuries; and KL1333 that is in phase I clinical trial for the treatment of genetic mitochondrial diseases. The company also develops NVP015/NV354 drug candidates for mitochondrial diseases; NVP025 drug candidate for mitochondrial myopathies; NV556 and NVP022 drug candidates for non-alcoholic steatohepatitis conditions; and NVP024, a hepatocellular carcinoma program. NeuroVive Pharmaceutical AB (publ) has collaboration agreements with Isomerase Therapeutics, Sihuan Pharmaceutical, and Sanofi Korea. NeuroVive Pharmaceutical AB has a partnership with TRACK-TBI; and has a preclinical collaboration agreement with the Children's Hospital of Philadelphia for research in genetic mitochondrial disorders. NeuroVive Pharmaceutical AB (publ) was founded in 2000 and is headquartered in Lund, Sweden.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/04/01 21:35|
|End of Day Share Price||2020/04/01 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.